{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-074426","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.218461+00:00","generated_at":"2026-06-17T23:00:56.275362+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Solid Biosciences presents one-year IGNITE DMD data; SGT-001 program concluded","bullets":["One-year data: mean 69.8% normal dystrophin by Western blot in 2E14 vg/kg cohort (Pt.5 at 18 months).","Motor function: 6MWT and NSAA showed positive mean change from baseline at 1 year.","Pulmonary function: FVC % predicted and FEV1 % predicted improved from baseline.","Safety: 2/9 SAEs related to SGT-001 (thrombocytopenia, hepatotoxicity, systemic inflammatory response).","SGT-001 program concluded; next-gen SGT-003 with novel capsid in IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-074426","json":"https://secwatch.observer/filing/0001193125-23-074426.json","markdown":"https://secwatch.observer/filing/0001193125-23-074426.md","text":"https://secwatch.observer/filing/0001193125-23-074426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312523074426/0001193125-23-074426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312523074426/d487716d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:00:56.275362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}